The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the investigational drug VER-01, developed by the German biopharmaceutical company VERTANICAL. This drug represents a first-in-class, non-opioid treatment derived from the cannabis plant, specifically designed for patients suffering from chronic low back pain. The FDA’s decision marks a major milestone in the field of chronic pain management, which has suffered from a profound lack of innovation for decades, relying heavily on opioids despite their high risk of addiction and severe side effects.
The designation is backed by positive results from two large-scale Phase 3 clinical trials. These studies demonstrated that VER-01 significantly reduces pain, exhibits favorable tolerability, and importantly, shows no signs of drug dependency or withdrawal symptoms. Furthermore, a direct head-to-head study against opioids revealed that this cannabis-based treatment is not only effective in pain relief but also offers much better gastrointestinal tolerance than traditional opioid analgesics. Patients also experienced substantial improvements in physical functioning and sleep quality, which is one of the greatest challenges in chronic pain management.
Technically, VER-01 is a standardized, full-spectrum extract obtained from a specific, proprietary strain of Cannabis sativa (DKJ127 L.). The company succeeded in developing a strictly defined phytochemical profile that combines cannabinoids, terpenes, and other bioactive compounds. The drug’s high pharmaceutical quality and consistent batch-to-batch stability are validated through advanced chromatographic and spectrometric methods, setting it apart from other cannabis products on the market, which often suffer from compositional variability.
The FDA’s Breakthrough Therapy designation is designed to expedite the development and review of promising drugs that demonstrate substantial improvement over existing therapies. According to Dr. Clemens Fischer, founder and CEO of VERTANICAL, this decision validates the drug’s immense potential and brings hope to millions of individuals who have been waiting for a safe and effective non-opioid alternative for years.
The company expects to receive marketing authorization in the first European countries in the coming weeks. Meanwhile, a supplementary clinical trial has already been initiated in the United States to meet local regulatory requirements. Based on the current timeline, VERTANICAL projects the readout of top-line data from the US study by 2027, with plans to submit a New Drug Application to the FDA in 2028 to make the treatment available to American patients.
